Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance

James L. Mulshine, Bruce E. Johnson, Adi F. Gazdar, Gail L. Shaw, Barnett S. Kramer, Tetsuya Mitsudomi, John D. Minna, Harvey Pass, Ruby Phelps, Bimal Ghosh, R. Ilona Linnoila, Daniel C. Ihde

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Consideration of a range of clinical and basic studies conducted at the National Cancer Institute which explore the nature of the tumor biology of lung identify the limitations of using chemotherapy for the treatment of advanced lung cancer. No single mechanistic explanation for lung cancer's chemoresistance is apparent, although considerable information about the biology of lung cancer and some of its clinical consequences have been elucidated. In contrast to previous works from our group, this presentation will focus principally on studies of the nature of drug resistance with non-small cell cancer. An alternative combined modality strategy for lung cancer control is to focus on epithelial progression of lung cancer using local modalities while it is still confined to the bronchial epithelium. Particular high risk populations may be appropriate to determine if local tools such as photodynamic laser therapy can be effective in this application. To deal with the underlying biochemical perturbations resulting from critical exposure of the bronchial epithelium to carcinogens, rational biochemical intervention with 13 cis retinoic acid are being evaluated in several clinical trials. An evolution towards more effective lung cancer.

Original languageEnglish (US)
JournalLung Cancer
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - 1994

Fingerprint

Drug Resistance
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Epithelium
Isotretinoin
National Cancer Institute (U.S.)
Photochemotherapy
Laser Therapy
Carcinogens
Clinical Studies
Neoplasms
Clinical Trials
Drug Therapy
Lung
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Mulshine, J. L., Johnson, B. E., Gazdar, A. F., Shaw, G. L., Kramer, B. S., Mitsudomi, T., ... Ihde, D. C. (1994). Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer, 10(SUPPL. 1). https://doi.org/10.1016/0169-5002(94)91669-1

Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. / Mulshine, James L.; Johnson, Bruce E.; Gazdar, Adi F.; Shaw, Gail L.; Kramer, Barnett S.; Mitsudomi, Tetsuya; Minna, John D.; Pass, Harvey; Phelps, Ruby; Ghosh, Bimal; Ilona Linnoila, R.; Ihde, Daniel C.

In: Lung Cancer, Vol. 10, No. SUPPL. 1, 1994.

Research output: Contribution to journalArticle

Mulshine, JL, Johnson, BE, Gazdar, AF, Shaw, GL, Kramer, BS, Mitsudomi, T, Minna, JD, Pass, H, Phelps, R, Ghosh, B, Ilona Linnoila, R & Ihde, DC 1994, 'Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance', Lung Cancer, vol. 10, no. SUPPL. 1. https://doi.org/10.1016/0169-5002(94)91669-1
Mulshine, James L. ; Johnson, Bruce E. ; Gazdar, Adi F. ; Shaw, Gail L. ; Kramer, Barnett S. ; Mitsudomi, Tetsuya ; Minna, John D. ; Pass, Harvey ; Phelps, Ruby ; Ghosh, Bimal ; Ilona Linnoila, R. ; Ihde, Daniel C. / Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. In: Lung Cancer. 1994 ; Vol. 10, No. SUPPL. 1.
@article{2f8702d48ff94f848ab8699046d8fd54,
title = "Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance",
abstract = "Consideration of a range of clinical and basic studies conducted at the National Cancer Institute which explore the nature of the tumor biology of lung identify the limitations of using chemotherapy for the treatment of advanced lung cancer. No single mechanistic explanation for lung cancer's chemoresistance is apparent, although considerable information about the biology of lung cancer and some of its clinical consequences have been elucidated. In contrast to previous works from our group, this presentation will focus principally on studies of the nature of drug resistance with non-small cell cancer. An alternative combined modality strategy for lung cancer control is to focus on epithelial progression of lung cancer using local modalities while it is still confined to the bronchial epithelium. Particular high risk populations may be appropriate to determine if local tools such as photodynamic laser therapy can be effective in this application. To deal with the underlying biochemical perturbations resulting from critical exposure of the bronchial epithelium to carcinogens, rational biochemical intervention with 13 cis retinoic acid are being evaluated in several clinical trials. An evolution towards more effective lung cancer.",
author = "Mulshine, {James L.} and Johnson, {Bruce E.} and Gazdar, {Adi F.} and Shaw, {Gail L.} and Kramer, {Barnett S.} and Tetsuya Mitsudomi and Minna, {John D.} and Harvey Pass and Ruby Phelps and Bimal Ghosh and {Ilona Linnoila}, R. and Ihde, {Daniel C.}",
year = "1994",
doi = "10.1016/0169-5002(94)91669-1",
language = "English (US)",
volume = "10",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance

AU - Mulshine, James L.

AU - Johnson, Bruce E.

AU - Gazdar, Adi F.

AU - Shaw, Gail L.

AU - Kramer, Barnett S.

AU - Mitsudomi, Tetsuya

AU - Minna, John D.

AU - Pass, Harvey

AU - Phelps, Ruby

AU - Ghosh, Bimal

AU - Ilona Linnoila, R.

AU - Ihde, Daniel C.

PY - 1994

Y1 - 1994

N2 - Consideration of a range of clinical and basic studies conducted at the National Cancer Institute which explore the nature of the tumor biology of lung identify the limitations of using chemotherapy for the treatment of advanced lung cancer. No single mechanistic explanation for lung cancer's chemoresistance is apparent, although considerable information about the biology of lung cancer and some of its clinical consequences have been elucidated. In contrast to previous works from our group, this presentation will focus principally on studies of the nature of drug resistance with non-small cell cancer. An alternative combined modality strategy for lung cancer control is to focus on epithelial progression of lung cancer using local modalities while it is still confined to the bronchial epithelium. Particular high risk populations may be appropriate to determine if local tools such as photodynamic laser therapy can be effective in this application. To deal with the underlying biochemical perturbations resulting from critical exposure of the bronchial epithelium to carcinogens, rational biochemical intervention with 13 cis retinoic acid are being evaluated in several clinical trials. An evolution towards more effective lung cancer.

AB - Consideration of a range of clinical and basic studies conducted at the National Cancer Institute which explore the nature of the tumor biology of lung identify the limitations of using chemotherapy for the treatment of advanced lung cancer. No single mechanistic explanation for lung cancer's chemoresistance is apparent, although considerable information about the biology of lung cancer and some of its clinical consequences have been elucidated. In contrast to previous works from our group, this presentation will focus principally on studies of the nature of drug resistance with non-small cell cancer. An alternative combined modality strategy for lung cancer control is to focus on epithelial progression of lung cancer using local modalities while it is still confined to the bronchial epithelium. Particular high risk populations may be appropriate to determine if local tools such as photodynamic laser therapy can be effective in this application. To deal with the underlying biochemical perturbations resulting from critical exposure of the bronchial epithelium to carcinogens, rational biochemical intervention with 13 cis retinoic acid are being evaluated in several clinical trials. An evolution towards more effective lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028273743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028273743&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(94)91669-1

DO - 10.1016/0169-5002(94)91669-1

M3 - Article

C2 - 8087530

AN - SCOPUS:0028273743

VL - 10

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -